Cargando…
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies
The treatment of advanced gastrointestinal (GI) cancers has become increasingly molecularly driven. Molecular profiling for HER2 and PD-L1 status is standard for metastatic gastroesophageal (GEJ) cancers to predict benefits from trastuzumab (HER2-targeted therapy) and pembrolizumab (anti-PD-1 therap...
Autores principales: | C. Huynh, Jasmine, Schwab, Erin, Ji, Jingran, Kim, Edward, Joseph, Anjali, Hendifar, Andrew, Cho, May, Gong, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281439/ https://www.ncbi.nlm.nih.gov/pubmed/32384640 http://dx.doi.org/10.3390/cancers12051168 |
Ejemplares similares
-
Immunotherapy Updates in Advanced Hepatocellular Carcinoma
por: Singh, Amisha, et al.
Publicado: (2021) -
Recent advances in the management of gastrointestinal stromal tumors
por: Duffaud, Florence, et al.
Publicado: (2010) -
Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
por: Lee, Patrick C., et al.
Publicado: (2021) -
Recent advances in gastrointestinal immunology
por: Materacki, Luke, et al.
Publicado: (2016) -
Recent advances in gastrointestinal cancers
por: Bordry, Natacha, et al.
Publicado: (2021)